- Home
- FENC
as 02-21-2025 12:36pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 156.9M | IPO Year: | 2001 |
| Target Price: | $14.00 | AVG Volume (30 days): | 55.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $11.49 | Next Earning Date: | 03-20-2025 |
| Revenue: | $49,348,000 | Revenue Growth: | 278.09% |
| Revenue Growth (this year): | 170.43% | Revenue Growth (next year): | 6.70% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RALLIS CHRIS A | FENC | Director | Feb 14 '25 | Sell | $6.82 | 1,186 | $8,088.52 | 53,020 | |
| Raykov Rosty | FENC | Director | Feb 5 '25 | Sell | $6.66 | 10,000 | $66,600.00 | 76,294 | |
| Raykov Rosty | FENC | Director | Jan 6 '25 | Sell | $6.08 | 10,000 | $60,800.00 | 76,294 | |
| Raykov Rosty | FENC | Director | Dec 5 '24 | Sell | $6.04 | 796 | $4,807.84 | 76,294 | |
| RALLIS CHRIS A | FENC | Director | Dec 2 '24 | Sell | $6.14 | 6,409 | $39,351.26 | 53,020 | |
| Raykov Rosty | FENC | Director | Dec 1 '24 | Sell | $6.13 | 1,635 | $10,022.55 | 76,294 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
MT Newswires
14 days ago
Fennec Pharmaceuticals Announces Commercial Launch of Pedmarqsi in Germany
MT Newswires
14 days ago
Fennec Pharmaceuticals' Pedmarqsi Launched in Germany by Norgine Pharmaceuticals
MT Newswires
2 months ago
Fennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales
MT Newswires
2 months ago
Fennec Gets "Positive Recommendation" for Pedmarqsi Use in England and Wales
GlobeNewswire
2 months ago
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
MT Newswires
2 months ago
Fennec Pharmaceuticals Makes Early Partial Repayment of Convertible Debt Facility With Petrichor
MT Newswires
2 months ago
Fennec Pharmaceuticals Partially Repays Convertible Debt Facility
GlobeNewswire
2 months ago
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.